Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Chakiryan, Nicholas H; Strother, Marshall C

Chakiryan, Nicholas H; Strother, Marshall C.

Affiliation

Chakiryan NH; Oregon Health and Science University, Portland, OR chakirya@ohsu.edu.
Strother MC; Oregon Health and Science University, Portland, OR chakirya@ohsu.edu.

N Engl J Med ; 391(2): 185-186, 2024 Jul 11.

Article in En | MEDLINE | ID: mdl-38986065

Subject(s)

Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Kidney Neoplasms; Humans; Male; Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Agents, Immunological/therapeutic use; Antineoplastic Agents, Immunological/adverse effects; Carcinoma, Renal Cell/drug therapy; Carcinoma, Renal Cell/mortality; Chemotherapy, Adjuvant; Kidney Neoplasms/drug therapy; Kidney Neoplasms/mortality; Nephrectomy; Clinical Trials as Topic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Kidney Neoplasms Limits: Humans / Male Language: En Journal: N Engl J Med Year: 2024 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google